Kilitch Drugs EBITDA vs. Profit Margin
| KILITCH Stock | 307.55 0.10 0.03% |
EBITDA | First Reported 2010-12-31 | Previous Quarter 287.4 M | Current Value 301.8 M | Quarterly Volatility 266.7 M |
For Kilitch Drugs profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Kilitch Drugs to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Kilitch Drugs Limited utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Kilitch Drugs's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Kilitch Drugs Limited over time as well as its relative position and ranking within its peers.
Kilitch |
Kilitch Drugs Limited Profit Margin vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Kilitch Drugs's current stock value. Our valuation model uses many indicators to compare Kilitch Drugs value to that of its competitors to determine the firm's financial worth. Kilitch Drugs Limited is currently regarded as number one stock in ebitda category among its peers. It also is currently regarded as number one stock in profit margin category among its peers . The ratio of EBITDA to Profit Margin for Kilitch Drugs Limited is about 3,454,627,404 . As of now, Kilitch Drugs' EBITDA is decreasing as compared to previous years. Comparative valuation analysis is a catch-all model that can be used if you cannot value Kilitch Drugs by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Kilitch Drugs' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Kilitch Profit Margin vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Kilitch Drugs |
| = | 287.43 M |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Kilitch Drugs |
| = | 0.08 % |
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
Kilitch Profit Margin Comparison
Kilitch Drugs is currently under evaluation in profit margin category among its peers.
Kilitch Drugs Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Kilitch Drugs, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Kilitch Drugs will eventually generate negative long term returns. The profitability progress is the general direction of Kilitch Drugs' change in net profit over the period of time. It can combine multiple indicators of Kilitch Drugs, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 287.1 M | 301.5 M | |
| Operating Income | 208.1 M | 218.5 M | |
| Income Before Tax | 193.6 M | 203.2 M | |
| Total Other Income Expense Net | -14.5 M | -13.8 M | |
| Net Income | 193.5 M | 203.2 M | |
| Income Tax Expense | 57.8 M | 30.1 M | |
| Net Income From Continuing Ops | 135.8 M | 142.5 M | |
| Net Income Applicable To Common Shares | 120.2 M | 126.2 M | |
| Net Interest Income | -59.3 M | -56.3 M | |
| Interest Income | 56.6 M | 59.4 M | |
| Change To Netincome | 49.6 M | 52.1 M |
Kilitch Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Kilitch Drugs. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Kilitch Drugs position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Kilitch Drugs' important profitability drivers and their relationship over time.
Use Kilitch Drugs in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kilitch Drugs position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kilitch Drugs will appreciate offsetting losses from the drop in the long position's value.Kilitch Drugs Pair Trading
Kilitch Drugs Limited Pair Trading Analysis
The ability to find closely correlated positions to Kilitch Drugs could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kilitch Drugs when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Kilitch Drugs - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Kilitch Drugs Limited to buy it.
The correlation of Kilitch Drugs is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Kilitch Drugs moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Kilitch Drugs Limited moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Kilitch Drugs can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Kilitch Drugs position
In addition to having Kilitch Drugs in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Junk Bonds Funds Thematic Idea Now
Junk Bonds Funds
Funds or Etfs that invest most of their assets into speculative (junk) bonds or to other fixed income instruments with interest rates 3 to 4 percentage points above government issues. The Junk Bonds Funds theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Junk Bonds Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Kilitch Stock
To fully project Kilitch Drugs' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Kilitch Drugs Limited at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Kilitch Drugs' income statement, its balance sheet, and the statement of cash flows.